GLP1R and hyperlipidemia: Our findings will inform future clinical preventative strategies including early diagnosis of diabetes and its complications; intensified management of hyperglycaemia with the use of newer treatments such (e.g. GLP 1 receptor agonists and SGLT 2 inhibitors); intensive, target‐driven management of cardiovascular risk factors (hypertension, hyperlipidaemia, smoking cessation and tailored exercise programmes), and reducing inequality in health by, for example, one‐stop screening services in deprived areas to increase the uptake of NICE recommended annual health checks.41, 43